JP Morgan Chase
EVH icon

JP Morgan Chase’s Evolent Health EVH Stock Holding History

JP Morgan Chase’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,900
Closed -$587K – 6844
2022
Q4 		$587K Buy
+20,900
New +$599K ﹤0.01% 4409

Other funds holding EVH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RPA
Rock Point Advisors Burlington, Vermont $409M AUM 30.68% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase's EVH Position: Q2 2026 in Review

JP Morgan Chase reduced its Evolent Health (EVH) stake by 84% in Q2 2026, selling an estimated $1.26M and leaving 61,050 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #5305.

JP Morgan Chase first reported a position in EVH in Q2 2015 and has held it in 45 quarters since. The position peaked at $210M in Q3 2022. 132 funds tracked by Wall St. Rank hold EVH as of Q2 2026.

  • JP Morgan Chase held 61,050 shares of Evolent Health worth $352K as of Q2 2026.
  • JP Morgan Chase sold 329,430 Evolent Health shares in Q2 2026, an estimated $1.26M.
  • Evolent Health made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5305 holding.
  • JP Morgan Chase first reported a position in Evolent Health in Q2 2015 and has held it in 45 quarters since.
  • JP Morgan Chase's Evolent Health position peaked at $210M in Q3 2022.
  • 132 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.